Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

BACKGROUND: Patients with resistant primary focal segmental glomerulosclerosis (FSGS) are at high risk of progression to chronic kidney disease stage V. Antifibrotic agents may slow or halt this process. We present outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Peyser, Alexandra, MacHardy, Nathaniel, Tarapore, Freya, MacHardy, Jacqueline, Powell, Leslie, Gipson, Debbie S, Savin, Virginia, Pan, Cynthia, Kump, Theresa, Vento, Suzanne, Trachtman, Howard
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2010
Matèries:
Research article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2823728/
https://ncbi.nlm.nih.gov/pubmed/20113498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2369-11-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars